X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RBI-4000 is a novel self-replicating RNA (srRNA) vaccine candidate, which stimulate virus-neutralizing immune responses to rabies. It is being developed for the treatment of rabies infection.
Lead Product(s): RBI-4000
Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-4000
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.
Lead Product(s): RBI-4000
Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-4000
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Curia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
RBI-4000, is an next generation srRNA technology vaccine developed to stimulate virus-neutralizing immune responses to rabies virus for prophylactic use.
Lead Product(s): RBI-4000
Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-4000
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
